Firefly Neuroscience Announces Greater Than 20-Fold Expansion Of Its Commercial Footprint, And 33-Fold Increase In Its EEG/ERP Scan Volumes

- Company reports 20-fold expansion of commercial footprint, 33-fold increase in EEG/ERP brain scan volumes - 

- Harnessing increased data and cutting-edge supercomputing potentially unlocks new AI-driven biomarker discovery capabilities and significantly advances Firefly on its path of building a foundation model of the human brain -

KENMORE, N.Y., March 04, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce a greater than 20-fold expansion of its commercial footprint, and a 33-fold Increase in its EEG/ERP scan volumes.

Through its acquisition of Evoke Neuroscience, Inc. and the successful execution of its key internal growth initiatives, Firefly ended 2025 partnered with 99 commercial users who completed a total of more than 10,800 EEG/ERP brain scans.

The year-over-year increases in partner sites and EEG/ERP clinical assessments represent growth of 1,880% and 3,227%, respectively, since the end of 2024.